Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Imperative Indications for Conservative Management of Upper Tract Transitional Cell Carcinoma
Krambeck, Amy E. , Thompson, R. Houston, Lohse, Christine M. , Patterson, David E., Elliott, Daniel S. , Blute, Michael L.

Mayo Clinic

Journal of Urology | July 17, 2007 | Volume: 178 | Issue: 3 | Pages: 792-797

10.1016/j.juro.2007.05.056 | PMID 17632132 Get It

WAVE2 Regulates High-Affinity Integrin Binding by Recruiting Vinculin and Talin to the Immunological Synapse
Nolz, Jeffrey C. , Medeiros, Ricardo B., Mitchell, Jason S. , Zhu, Peimin, Freedman, Bruce D. , Shimizu, Yoji , Billadeau, Daniel D.

Mayo Clinic

Molecular and Cellular Biology | June 26, 2007 | Volume: 27 | Issue: 17 | Pages: 5986-6000

10.1128/mcb.00136-07 | PMID 17591693 Get It

Desmoplastic Melanoma of the Head and Neck: Histopathologic and Immunohistochemical Study of 28 Cases
Kay, Paul , Pinheiro, A. Daniel, Lohse, Christine M. , Olsen, Kerry D., Lewis, Jean E., Pankratz, V. Shane , Nascimento, Antonio G.

Mayo Clinic

International Journal of Surgical Pathology | June 21, 2007 | Volume: 12 | Issue: 1 | Pages: 17-24

10.1177/106689690401200103 | PMID 14765268 Get It

Studies of the immunohistochemical profiles and clinical course of desmoplastic melanoma have produced conflicting results. We identified 28 cases of desmoplastic melanoma after a search of our files for spindle cell neoplasms of the head and neck from 1960 through 1995. The 17 male (61%) and 11 female (39%) patients averaged 65 years of age. The cheek was the most common location (12 cases, 43%). The average length of follow-up was 5 years. Overall 5-year survival rate was 46%. Melan A and tyrosinase positivity (P = 0.0195), smooth muscle actin positivity (P = 0.0328), tumor size (P = 0.0297), and tumor thickness (P = 0.0419) were significantly associated with local progression-free survival. No histologic or immunohistochemical marker was associated with overall or metastasis-free survival.
Pediatric Pain Measurement Using a Visual Analogue Scale: A Comparison of Two Teaching Methods
Shields, Brenda J., Cohen, Daniel M. , Harbeck‐Weber, Cynthia , Powers, Jean D., Smith, Gary A. , Harbeck‐Weber, Cynthia

Mayo Clinic

Clinical Pediatrics | June 21, 2007 | Volume: 42 | Issue: 3 | Pages: 227-234

10.1177/000992280304200306 | PMID 12739921 Get It

The goals of this study were to evaluate the validity of the visual analogue scale (VAS) for young children and to compare a newly developed method of teaching children to use a VAS with one used in our previous studies. It was hypothesized that the new method would increase the number of children who understand the VAS and correctly mark their responses on the VAS line. The association between child's age and ability to understand the VAS was also evaluated. One hundred-six children with a laceration requiring sutures and receiving a lidocaine injection for local anesthesia participated in the study. They ranged in age from 5 to 14 years. Two outcome measures were used to assess the baseline and lidocaine injection pain: a 5-point Likert scale and a VAS. A calibration study was used to determine whether the subjects were able to use the VAS to make proportional judgments about their perceptions. Teaching method had no effect on the number of subjects who could correctly mark their responses on the VAS line, nor did it significantly increase the number of subjects who could understand the concept of the VAS. Subjects who were able to understand the VAS were significantly older (mean = 9.8 years, SD = 2.8) than those who did not (mean = 8.2 years, SD = 2.5). Overall, only about one third of the subjects were able to correctly mark the VAS and understand the concept of the VAS. Other measures of pain that are better understood by young children may be more valid indicators of pain than the VAS.
Stability of the loaded ankle
Stormont, Daniel M., Morrey, B.F. , An, Kai‐Nan , Cass, Joseph R.

Mayo Clinic

The American Journal of Sports Medicine | June 21, 2007 | Volume: 13 | Issue: 5 | Pages: 295-300

10.1177/036354658501300502 | PMID 4051085 Get It

The stabilizing capacity of the ligaments and articular surface in the ankle was determined under defined physiologic loading conditions. The concept of primary and secondary constraints was adapted to the ankle. With physiologic loading, the articular surface ac counted for 30% and 100% of stability in rotation and version, respectively. That the articular surface was the sole source of inversion and eversion stability under the prescribed physiologic loading conditions has not been previously reported. The demonstration that the articular surface resists inversion displacement in the loaded ankle supports the conclusion of previous studies that rotation, rather than inversion, may account for a type of clinically sympto matic ankle instability. Further, ankle instability may occur during loading and unloading but not once the ankle is fully loaded. The results of our study confirm the importance of the anterior talofibular and calcaneo fibular ligaments and suggest an important role for the deltoid ligament.
Stratification of Breast Cancer Risk in Women With Atypia: A Mayo Cohort Study
Visscher, Daniel W., Berman, Hal K. , Frost, Marlene H., Sellers, Thomas A. , Vierkant, Robert A. , Maloney, Shaun D., Groen, Piet C. de , Lingle, Wilma L., Ghosh, Karthik, Penheiter, Lois, Tlsty, Thea D. , Melton, L. Joseph , Reynolds, Carol, Hartmann, Lynn C. , Degnim, Amy C. , Pankratz, V. Shane , Vierkant, Robert A

Mayo Clinic

Journal of Clinical Oncology | June 12, 2007 | Volume: 25 | Issue: 19 | Pages: 2671-2677

10.1200/jco.2006.09.0217 | PMID 17563394 Get It

Purpose Atypical hyperplasia is a well-recognized risk factor for breast cancer, conveying an approximately four-fold increased risk. Data regarding long-term absolute risk and factors for risk stratification are needed. Patients and Methods Women with atypical hyperplasia in the Mayo Benign Breast Disease Cohort were identified through pathology review. Subsequent breast cancers were identified via medical records and a questionnaire. Relative risks (RRs) were estimated using standardized incidence ratios, comparing the observed number of breast cancers with those expected based on Iowa Surveillance, Epidemiology, and End Results (SEER) data. Age, histologic factors, and family history were evaluated as risk modifiers. Plots of cumulative breast cancer incidence provided estimates of risk over time. Results With mean follow-up of 13.7 years, 66 breast cancers (19.9%) occurred among 331 women with atypia. RR of breast cancer with atypia was 3.88 (95% CI, 3.00 to 4.94). Marked elevations in risk were seen with multifocal atypia (eg, three or more foci with calcifications [RR, 10.35; 95% CI, 6.13 to 16.4]). RR was higher for younger women (< 45; RR, 6.76; 95% CI, 3.24 to 12.4). Risk was similar for atypical ductal and atypical lobular hyperplasia, and family history added no significant risk. Breast cancer risk remained elevated over 20 years, and the cumulative incidence approached 35% at 30 years. Conclusion Among women with atypical hyperplasia, multiple foci of atypia and the presence of histologic calcifications may indicate “very high risk” status (> 50% risk at 20 years). A positive family history does not further increase risk in women with atypia.
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
O’Dwyer, Peter J. , Haller, Daniel G. , Tepper, Joel E. , Ahnen, Dennis J. , Benson, Al B. , Rothenberg, Mace L., Petrelli, Nicholas J. , Lenz, Heinz‐Joseph, Diasio, Robert B. , Dubois, Raymond, Sargent, Daniel J. , Sloan, Jeff A. , Johnson, C. Daniel, Comis, Robert L., Eckhardt, Sabine , Hamilton, Stanley R. , O’Connell, Michael J. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | May 30, 2007 | Volume: 25 | Issue: 16 | Pages: 2313-2321

10.1200/jco.2006.08.6900 | PMID 17538178 Get It

Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer
Cunningham, Julie M. , Hebbring, Scott J. , McDonnell, Shannon K. , Cicek, Mine S., Christensen, G. Bryce , Jacobsen, Steven J. , Cerhan, James R. , Blute, Michael L., Schaid, Daniel J. , Thibodeau, Stephen N. , Wang, Liang , Cerhan, James R , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 16, 2007 | Volume: 16 | Issue: 5 | Pages: 969-978

10.1158/1055-9965.epi-06-0767 | PMID 17507624 Get It

AbstractPrevious studies suggest that enzymes involved in the androgen metabolic pathway are susceptibility factors for prostate cancer. Estrogen metabolites functioning as genotoxins have also been proposed as risk factors. In this study, we systematically tested the hypothesis that common genetic variations for those enzymes involved in the androgen and estrogen metabolic pathways increase risk for sporadic and familial prostate cancer. From these two pathways, 46 polymorphisms (34 single nucleotide polymorphisms, 10 short tandem repeat polymorphisms, and 2 null alleles) in 25 genes were tested for possible associations. Those genes tested included PRL, LHB, CYP11A1, HSD3B1, HSD3B2, HSD17B2, CYP17, SRD5A2, AKR1C3, UGT2B15, AR, SHBG, and KLK3 from the androgen pathway and CYP19, HSD17B1, CYP1A1, CYP1A2, CYP1B1, COMT, GSTP1, GSTT1, GSTM1, NQO1, ESR1, and ESR2 from the estrogen pathway. A case-control study design was used with two sets of cases: familial cases with a strong prostate cancer family history (n = 438 from 178 families) and sporadic cases with a negative prostate cancer family history (n = 499). The controls (n = 493) were derived from a population-based collection. Our results provide suggestive findings for an association with either familial or sporadic prostate cancer with polymorphisms in four genes: AKR1C3, HSD17B1, NQO1, and GSTT1. Additional suggestive findings for an association with clinical variables (disease stage, grade, and/or node status) were observed for single nucleotide polymorphisms in eight genes: HSD3B2, SRD5A2, SHBG, ESR1, CYP1A1, CYP1B1, GSTT1, and NQO1. However, none of the findings were statistically significant after appropriate corrections for multiple comparisons. Given that the point estimates for the odds ratio for each of these polymorphisms are &lt;2.0, much larger sample sizes will be required for confirmation. (Cancer Epidemiol Biomarkers Prev 2007;16(5):969–78)
Adjuvant Therapy in the Elderly: Making the Right Decision
Muss, Hyman B. , Biganzoli, Laura , Sargent, Daniel J. , Aapro, Matti , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | May 8, 2007 | Volume: 25 | Issue: 14 | Pages: 1870-1875

10.1200/jco.2006.10.3457 | PMID 17488985 Get It

Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non–small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non–small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.